bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
BofA Securities 2023 Health Care Conference Read more about BofA Securities 2023 Health Care Conference
bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events Read more about bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events Read more about bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
bluebird bio 4th Quarter & Full Year 2022 Earnings Call Read more about bluebird bio 4th Quarter & Full Year 2022 Earnings Call
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock Read more about bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock Read more about bluebird bio, Inc. Announces Proposed Public Offering of Common Stock